Publications by authors named "R Garcia-Campelo"
Article Synopsis
- - The NADIM trial was a phase 2 study in Spain that evaluated the effects of perioperative immunotherapy on long-term outcomes in patients with stage IIIA non-small-cell lung cancer (NSCLC), showing positive short-term results previously. - A total of 46 treatment-naive patients participated, receiving a combination of chemotherapy and nivolumab before surgery, followed by more nivolumab as adjuvant therapy, with the study measuring 5-year progression-free and overall survival rates. - Findings showed that after 5 years, 65% of patients were progression-free and 69% had overall survival, with disease progression seen in 24% of patients and 30% dying by the end of the follow-up period.
Article Synopsis
- Liquid biopsy (LB) with FoundationOne Liquid CDx (F1L CDx) offers a non-invasive way to detect genetic changes in advanced non-small cell lung cancer (NSCLC) patients when tissue biopsies aren't possible, and this study assesses its cost-effectiveness in Spain.
- In a model evaluating 1,000 patients, F1L CDx identified 386 alterations, enabling targeted treatments and yielding significant health benefits compared to traditional non-molecular diagnosis, evidenced by an additional 383.95 life years (LYs) and 305.94 quality-adjusted life years (QALYs) despite a higher overall cost of €2,898,308.
- The analysis concludes that F1L CDx
Objectives: Lung Cancer (LC) is a multifactorial disease for which the role of genetic susceptibility has become increasingly relevant. Our aim was to use artificial intelligence (AI) to analyze differences between patients with LC based on family history of cancer (FHC).
Materials And Methods: From August 2016 to June 2020 clinical information was obtained from Thoracic Tumors Registry (TTR), a nationwide database sponsored by the Spanish Lung Cancer Group.
The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation.
View Article and Find Full Text PDFBackground: Early detection is crucial to improve lung cancer survival rates. Delays in diagnosis might negatively impact the prognosis of the disease. This study aims to analyze the diagnostic delay in lung cancer patients and describe if there is an association between delay and survival.
View Article and Find Full Text PDF